Skip to main content
Clinical Trials/NCT02911051
NCT02911051
Completed
N/A

Clinical Study Evaluating the Safety of a New Catheter for Urinary Intermittent Catheterization in Self Catheterized Patients

BBraun Medical SAS1 site in 1 country22 target enrollmentSeptember 2, 2016

Overview

Phase
N/A
Intervention
Not specified
Conditions
Intermittent Urethral Catheterization
Sponsor
BBraun Medical SAS
Enrollment
22
Locations
1
Primary Endpoint
Safety of Hydrolite Cath will be demonstrated by listing any adverse event(s) related to the use of Actreen® Hydrolite Cath and other occurrence
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

The clinical study evaluates the safety of a new catheter for Urinary Intermittent Catheterisation in self catheterized patients

Registry
clinicaltrials.gov
Start Date
September 2, 2016
End Date
May 3, 2017
Last Updated
8 years ago
Study Type
Interventional
Study Design
Single Group
Sex
Male

Investigators

Sponsor
BBraun Medical SAS
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • male patient
  • patient is at least 18 years old
  • patient having normal or impaired sensation in the urethra
  • patient catheterizing at least 4 times a day
  • patient using Ch 12 or 14 catheter for self clean urinary catheterization
  • patient using a Nelaton catheter for self clean urinary catheterization
  • patient using self clean urinary catheterization for at least one month
  • patient covered with social insurance

Exclusion Criteria

  • patient having a symptomatic urinary tract infection as assessed by the investigator (5 days after end of treatment for UTI, patient can be considered by the investigator for inclusion)
  • patient with urethral hypersensitivity
  • patient being mentally unstable not being assessed by the investigator as capable to follow the study procedure
  • patient already participating in another clinical study or who have previously participated in this investigation

Outcomes

Primary Outcomes

Safety of Hydrolite Cath will be demonstrated by listing any adverse event(s) related to the use of Actreen® Hydrolite Cath and other occurrence

Time Frame: All adverse event(s) occured during the 7 (±1) days, related to the use of Actreen Hydrolite Cath, will be registered.

Study Sites (1)

Loading locations...

Similar Trials